Carregant...
The Preclinical Discovery and Development of Bortezomib for the Treatment of Mantle Cell Lymphoma
INTRODUCTION: Mantle cell lymphoma (MCL) is an incurable, often aggressive B-cell malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and approved for treatment of relapsed refractory multiple myeloma, and subsequently approved for treatment of MCL. BTZ’s single-agent...
Guardat en:
| Publicat a: | Expert Opin Drug Discov |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5520581/ https://ncbi.nlm.nih.gov/pubmed/27917682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17460441.2017.1268596 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|